Now, a study in Genes & Diseases reports a previously unrecognized epigenetic route through which the iron-responsive protein IRP1 collaborates with the transcription factor ARID3A to suppress ferroptosis and promote chemoresistance. The work links iron sensing to chromatin regulation and identifies a pathway that could be exploited therapeutically.

Across pancreatic cancer specimens, the authors find that both IRP1 and ARID3A are highly expressed and correlate with poor chemotherapy outcomes and unfavorable patient survival. In cell-based functional assays, elevating either protein enhances proliferation and increases resistance to gemcitabine, while silencing IRP1 or ARID3A restores chemosensitivity and suppresses tumor growth in models.

Mechanistically, intracellular iron accumulation drives IRP1 into the nucleus, where it physically associates with ARID3A. Rather than altering transcription solely through classic repression, the IRP1–ARID3A complex remodels chromatin dynamics to reduce accessibility at the cytoglobin (CYGB) promoter. This epigenetic shift suppresses CYGB expression without relying on direct transcriptional shutdown.

CYGB, in turn, plays a role in maintaining redox balance and regulating oxidative stress responses. When CYGB is diminished, pancreatic cancer cells show reduced lipid peroxidation, less reactive oxygen species accumulation, and stronger survival under ferroptosis-inducing conditions. The study connects these biochemical changes directly to the observed drug-resistant phenotype.

Crucially, restoring CYGB or disrupting the IRP1–ARID3A interaction reverses the ferroptosis-resistant state, resensitizing cells to ferroptosis and improving gemcitabine efficacy. In vivo, combining ferroptosis-relevant interventions with suppression of this signaling axis markedly restricts tumor progression.

The findings position the IRP1–ARID3A–CYGB axis as a central determinant of ferroptosis resistance in pancreatic cancer. By uniting iron metabolism, epigenetic control, and regulated cell death, the work offers a mechanistic basis for pairing chemotherapy with ferroptosis-targeting strategies in patients who do not respond to standard treatment.

Subject of Research: Ferroptosis resistance and chemoresistance in pancreatic cancer via IRP1–ARID3A–CYGB epigenetic regulation

Article Title: IRP1/ARID3A complex promotes pancreatic cancer chemoresistance by suppressing CYGB-related ferroptosis

News Publication Date:

Web References: http://dx.doi.org/10.1016/j.gendis.2025.101866

References:

Image Credits:

Keywords: pancreatic cancer; ferroptosis; IRP1; ARID3A; CYGB; chemoresistance; epigenetics; iron metabolism; gemcitabine

CoQ10, a lipophilic molecule embedded within the inner mitochondrial membrane, functions fundamentally as an electron carrier in the mitochondrial respiratory chain. However, emerging evidence positions CoQ10 oxidoreductases as critical modulators of redox balance, influencing a cell’s propensity to undergo ferroptosis. Ferroptosis is characterized by iron-driven accumulation of lipid-based reactive oxygen species (ROS), disrupting cellular membranes and leading to an oxidative demise distinct from apoptosis or necrosis. This pathway has garnered attention for its potential to selectively target cancer cells resistant to conventional apoptosis-inducing therapies.

The research team deciphers how CoQ10 oxidoreductases exert a finely-tuned redox regulation, effectively governing ferroptotic sensitivity. These enzymes catalyze the reduction of CoQ10, sustaining its antioxidant capacity to mitigate lipid peroxidation. Intriguingly, certain cancers exhibit dysregulated expression or activity of these oxidoreductases, skewing the redox balance and fostering resistance against ferroptotic triggers. This mechanistic insight deepens our understanding of how cancer cells adapt to oxidative stress, potentially exploiting CoQ10 pathways to evade death.

A central revelation from the study is how CoQ10 oxidoreductase activity functions not only as a metabolic safeguard but also as a regulatory nexus controlling lipid peroxide detoxification. By reducing CoQ10, these enzymes replenish ubiquinol pools—powerful chain-breaking antioxidants that inhibit the propagation of lipid radicals in membranes. This antioxidative shield forms a biochemical barrier against ferroptotic induction, supporting cancer cell survival amid fluctuating oxidative milieus.

Ferroptosis has emerged as a compelling alternative to traditional apoptosis-centered therapies, particularly in malignancies exhibiting refractory resistance or mutated apoptotic machinery. The modulation of CoQ10 oxidoreductases, therefore, uncovers a therapeutic opportunity to sensitize tumors to ferroptotic death. Pharmacological inhibition or genetic suppression of these enzymes could dismantle the antioxidative defenses, augmenting lipid peroxidation and tipping the scales toward ferroptosis. Such strategies may offer a precision oncology approach, exploiting metabolic vulnerabilities while sparing normal tissues.

Adding complexity, the study highlights the context-dependent roles of different CoQ10 oxidoreductases isoforms across various cancer types. Some enzymes are upregulated, conferring enhanced ferroptosis resistance, whereas others might paradoxically promote oxidative stress under specific metabolic states. This heterogeneity accentuates the necessity for tailored therapeutic designs considering tumor-specific redox landscapes and CoQ10 enzymatic profiles.

Moreover, the researchers explore the cross-talk between CoQ10 oxidoreductases and other ferroptosis regulators, such as glutathione peroxidase 4 (GPX4) and membrane lipid remodeling enzymes. Inhibitory effects on CoQ10 oxidoreductases synergize with GPX4-targeting agents, generating combinatorial lethality that dismantles both lipid peroxide scavenging and detoxification pathways. This dual targeting could overcome resistance mechanisms and potentiate ferroptotic responses in challenging cancer subtypes.

Beyond its anti-ferroptotic functions, CoQ10 reduction by these oxidoreductases indirectly influences mitochondrial bioenergetics and ROS generation, highlighting an intricate feedback loop intertwining metabolic flux and redox signaling. As cancer cells often rewire mitochondrial dynamics to fuel aggressive phenotypes, manipulating CoQ10 oxidoreductase activity could disrupt cellular energetics, further sensitizing tumors to ferroptotic death.

The therapeutic implications of these findings are manifold. Small molecules modulating CoQ10 oxidoreductase activity offer a promising class of anticancer agents. Currently, several inhibitors are in preclinical evaluation, aiming to destabilize ubiquinol regeneration and collapse cellular redox defenses. Nanotechnology-enhanced delivery systems engineered to target tumors could also enhance drug specificity, reducing off-target effects and oxidative toxicity to healthy tissues.

Translationally, the elucidation of CoQ10 oxidoreductases as ferroptosis gatekeepers may provide prognostic biomarkers for patient stratification. Expression levels or enzymatic activity profiles could predict tumor susceptibility to ferroptosis-inducing therapies, enabling more personalized treatment regimens. Additionally, monitoring redox metabolites derived from CoQ10 pathways may serve as dynamic markers of therapeutic response.

Despite these advances, challenges remain in fully deciphering the intricate regulation of ferroptosis by CoQ10 oxidoreductases. Tumor microenvironment factors such as hypoxia, nutrient availability, and iron metabolism intricately modulate ferroptotic outcomes and CoQ10 enzyme function. Future studies must integrate multi-omic and spatial profiling to map these interactions comprehensively, paving the way for sophisticated intervention strategies.

In conclusion, the pioneering work of Lee and colleagues spotlights CoQ10 oxidoreductases as critical arbiters of ferroptotic cell death in cancer, functioning through redox regulation of lipid peroxide detoxification and cellular bioenergetics. Their dual role in shielding tumor cells and offering a therapeutic Achilles’ heel heralds a new chapter in redox biology and cancer therapy. As ferroptosis-based interventions advance toward clinical reality, targeting CoQ10 oxidoreductases emerges as a promising strategy to overcome drug resistance and improve patient outcomes in the relentless battle against cancer.

The implications of these findings extend beyond oncology, potentially informing therapeutic approaches for other diseases characterized by dysregulated redox homeostasis and lipid peroxidation, including neurodegeneration and cardiovascular disorders. The nuanced understanding of CoQ10 oxidoreductase function thus heralds broader biomedical significance, representing a cornerstone of future redox medicine.

Subject of Research:
CoQ10 oxidoreductases in ferroptosis regulation and cancer therapy

Article Title:
CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities.

Article References:
Lee, J., Yoo, I., Kim, M. et al. CoQ₁₀ oxidoreductases in ferroptosis and cancer: redox regulation and therapeutic opportunities. Exp Mol Med (2026). https://doi.org/10.1038/s12276-026-01736-w

Image Credits: AI Generated

DOI: 03 June 2026

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, and despite significant advances, effective treatments with minimal side effects are still in high demand. The recent findings shed light on an innovative natural strategy, leveraging bacterial proteins combined with oleate, a common fatty acid, to trigger cancer cell death. This approach diverges from traditional chemotherapies, focusing instead on biochemical modulation of the tumor microenvironment and intracellular signaling.

Central to the study is the concept of ferroptosis, a distinctive cell death pathway characterized by iron-dependent lipid peroxidation and membrane damage. Unlike apoptosis or necrosis, ferroptosis culminates in catastrophic impairment of the cell membrane integrity, leading to cell demise. The research highlights how bacterial protein-oleate complexes wield this mechanism by disrupting the delicate balance of cellular redox states within colorectal cancer cells.

A pivotal component in this mechanism involves the β-catenin-GPX4 axis—a critical molecular pathway governing cellular proliferation and antioxidative defense. β-catenin is widely recognized for its role in cell adhesion and gene transcription within the canonical Wnt signaling pathway, which is frequently deregulated in colorectal cancers. GPX4 (glutathione peroxidase 4), on the other hand, acts as a guardian against oxidative membrane damage by reducing lipid peroxides. The study reveals that these bacterial protein-oleate complexes inhibit this protective axis, thereby sensitizing cancer cells to ferroptosis-like death.

The researchers utilized a meticulous experimental design combining biochemical assays, molecular biology techniques, and high-resolution imaging to dissect the interaction between bacterial factors and cancer cell membranes. Their data confirm that the complexes integrate into the lipid bilayer, inducing permeabilization accompanied by oxidative stress. This process precipitates the collapse of oncogenic β-catenin signaling, further amplifying cellular distress and leading to irreversible damage.

Moreover, the study explores the therapeutic potential of leveraging gut microbiota-derived components to modulate cancer progression. The interplay between the microbiome and host cellular physiology has attracted considerable interest, and these findings suggest that specific bacterial proteins complexed with fatty acids can be harnessed as bioactive agents to selectively kill cancer cells. This represents a compelling example of how microbiota metabolism might be redirected to benefit cancer therapy.

Of particular note is the ability of bacterial protein-oleate complexes to overcome resistance mechanisms typically encountered in colorectal cancer treatment. Many tumors develop heightened antioxidant defenses to evade ferroptotic death, primarily through the upregulation of GPX4 and related enzymes. By directly targeting and inhibiting the β-catenin-GPX4 axis, these complexes introduce an innovative strategy to bypass such resistance and effectively induce cell death.

This study’s in vitro models demonstrated significant cytotoxic effects on colorectal cancer cells with minimal impact on non-cancerous colon epithelial cells, suggesting a measure of selectivity and safety. Such selectivity is a crucial consideration for the translation of these findings into clinical applications, minimizing collateral damage to healthy tissue during treatment.

Further analysis revealed that the bacterial protein component is essential for the targeting and delivery of oleate into cancer cells, indicating a sophisticated mechanism of uptake and membrane interaction. This protein-facilitated oleate delivery enhances membrane perturbation and ensures effective inhibition of β-catenin signaling, culminating in pronounced ferroptotic activity.

The implications of these findings extend beyond colorectal cancer, as the molecular pathways affected—particularly GPX4-mediated lipid repair—are conserved across various cancer types. This raises the exciting possibility that bacterial protein-fatty acid complexes could serve as a platform technology, adapted to multiple malignancies characterized by dysregulated redox homeostasis and membrane integrity.

In addressing future research directions, the authors underscore the necessity for in vivo validation using animal cancer models to examine pharmacodynamics, biodistribution, and possible immune system interactions. Understanding the complex immunological landscape will be paramount, given that ferroptotic cell death can modulate immune responses, potentially enhancing antitumor immunity in combination with other immunotherapies.

Interestingly, the study opens doors to biotechnological innovation, encouraging the design of engineered bacterial proteins with enhanced oleate-binding capabilities or modified fatty acid profiles to tailor therapeutic effects. Such bioengineering endeavors could optimize potency and specificity, translating this natural mechanism into clinically viable drug candidates.

This breakthrough also challenges the conventional view that bacterial metabolites primarily contribute to cancer progression or inflammation. Instead, it positions select bacterial products as strategic effectors capable of reprogramming tumor survival pathways. Harnessing microbial biochemistry in this manner stands at the crossroads of oncology, microbiology, and pharmacology, heralding a new paradigm in cancer treatment.

Finally, this research reflects a growing trend towards integrating multidimensional approaches that include microbiome modulation, targeted molecular interference, and lipid-mediated cell death pathways. By uniting these fields, it offers a holistic and innovative approach to combat one of the most stubborn and deadly types of cancer, providing hope for improved patient outcomes and personalized therapies.

In conclusion, bacterial protein-oleate complexes represent a potent and selective inducer of ferroptosis-like death in colorectal cancer cells, acting through disruption of cell membranes and inhibition of the β-catenin-GPX4 survival axis. This work provides a visionary outlook on exploiting microbial molecules for next-generation cancer therapeutics, and ongoing studies will determine its full applicability in clinical oncology.

Subject of Research: Colorectal cancer cell death mechanisms induced by bacterial protein-oleate complexes

Article Title: Bacterial protein-oleate complexes induce ferroptosis-like cell death in colorectal cancer cells by disrupting cell membranes and inhibiting the β-catenin-GPX4 axis

Article References: Ullah, N., Yabrag, A., Ali, A. et al. Bacterial protein-oleate complexes induce ferroptosis-like cell death in colorectal cancer cells by disrupting cell membranes and inhibiting the β-catenin-GPX4 axis. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03097-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03097-9

Melanoma remains one of the most aggressive forms of skin cancer, often exhibiting resistance to conventional treatments like chemotherapy and targeted therapies. This resistance has fueled an intense search for novel approaches that can selectively trigger cancer cell death while sparing healthy tissues. Ferroptosis, discovered only about a decade ago, has emerged as an intriguing target for oncology due to its distinct biochemical pathway involving iron-dependent lipid peroxidation. However, its precise regulatory mechanisms, particularly in melanoma, remained elusive until now.

AMPK acts as a master regulator of cellular energy homeostasis, responding dynamically to metabolic stress by modulating multiple downstream pathways. Previously, AMPK’s role in cancer had been viewed largely through the lens of metabolic checkpoint control, but this study extends its function into the governance of lipid droplet biogenesis and turnover. Lipid droplets, long considered inert fat storage structures, are increasingly recognized as active participants in cell signaling and stress responses. The study reveals how AMPK regulates lipid droplet dynamics to influence melanoma cells’ sensitivity to ferroptosis, particularly when challenged with polyunsaturated fatty acids (PUFAs) and iron.

The researchers demonstrated that activation of AMPK promotes the formation and turnover of lipid droplets containing polyunsaturated fatty acids, which are highly susceptible to peroxidation. This lipid remodeling primes melanoma cells for ferroptosis by fostering an intracellular environment rich in oxidizable lipids. Concurrently, AMPK-mediated control of iron metabolism ensures sufficient catalytic iron is available to drive lipid peroxidation, effectively setting a cellular trap that induces ferroptotic cell death.

Experimentally, the team employed both genetic and pharmacological tools to manipulate AMPK activity and observed corresponding changes in lipid droplet morphology and composition. Increased AMPK activity correlated with heightened lipid droplet formation enriched in PUFA species, amplifying the cells’ sensitivity to ferroptosis-inducing agents. Conversely, inhibition of AMPK disrupted lipid droplet dynamics, conferring resistance to ferroptosis and underscoring AMPK’s pivotal regulatory role.

This link between lipid droplet handling and ferroptosis sensitivity is particularly significant in the context of the tumor microenvironment, where availability of PUFAs can vary greatly. The study suggests that melanoma cells may leverage AMPK pathways to adapt dynamically to fluctuating nutrient and oxidative conditions, thus modulating their vulnerability to ferroptosis as a survival strategy. Targeting this adaptive mechanism could render melanoma cells less capable of escaping ferroptotic death when exposed to therapeutic interventions.

Moreover, the data highlight how iron metabolism intersects with lipid droplet dynamics under AMPK control. Since iron catalyzes the peroxidation of PUFAs, cellular iron homeostasis is integral to ferroptosis execution. The research elucidates how AMPK influences expression of key iron transporters and storage proteins, tuning intracellular iron pools to promote efficient ferroptotic signaling. This multi-layered control underscores the sophisticated cellular integration of metabolic and oxidative stress pathways governing melanoma fate.

The implications of this work extend beyond melanoma, potentially informing therapeutic strategies for other cancers characterized by altered lipid metabolism and iron handling. By exploiting the AMPK-lipid droplet-ferroptosis axis, clinicians may develop combinatorial treatments that synergize metabolic modulators with ferroptosis inducers, achieving more effective tumor eradication. Such approaches could overcome resistance mechanisms that stymie current therapies, improving patient outcomes.

Significantly, this study challenges the traditional view of lipid droplets as passive lipid stores, recasting them as dynamic organelles that mediate critical cell death pathways. The intimate crosstalk between energy sensing, lipid remodeling, and ferroptotic susceptibility opens new research directions into cellular stress responses and tumor biology. It also raises the possibility that metabolic states and nutrient availability directly influence cancer cell vulnerability via lipid droplet regulation.

Future investigations will be crucial for dissecting the precise molecular players linking AMPK signaling to lipid droplet dynamics and iron metabolism in various cancer contexts. Understanding how these pathways differ between tumor types, stages, and microenvironmental conditions will be essential for translating these findings into clinical interventions. Additionally, exploring how metabolic therapies can be combined with immunotherapies or targeted drug regimens could yield synergistic effects harnessing ferroptosis pathways.

Another exciting avenue lies in the development of novel ferroptosis biomarkers based on lipid droplet composition and AMPK activity, which could predict tumor responsiveness and guide personalized treatments. Detection of lipid peroxidation signatures or iron metabolic profiles might inform real-time monitoring of ferroptotic engagement during therapy, enhancing precision medicine approaches.

In summary, Motamedi and colleagues have provided a landmark insight into how AMPK-driven lipid droplet dynamics orchestrate melanoma’s sensitivity to ferroptosis via modulation of polyunsaturated fatty acid availability and iron metabolism. By illuminating this intricate regulatory nexus, their work paves the way for novel metabolic and ferroptotic interventions against melanoma and potentially other refractory cancers. As the field moves forward, targeting lipid droplet biology alongside ferroptosis represents a promising frontier in cancer therapeutics that could finally turn the tide against treatment-resistant tumors.

Subject of Research: The regulation of ferroptosis sensitivity in melanoma cells by AMP-activated protein kinase (AMPK)-mediated lipid droplet dynamics.

Article Title: AMP-activated protein kinase-driven lipid droplet dynamics govern melanoma sensitivity to polyunsaturated fatty acid and iron-induced ferroptosis.

Article References:
Motamedi, S., Ravoet, N., Dehairs, J. et al. AMP-activated protein kinase-driven lipid droplet dynamics govern melanoma sensitivity to polyunsaturated fatty acid and iron-induced ferroptosis. Nat Commun (2025). https://doi.org/10.1038/s41467-025-66113-z

Image Credits: AI Generated

Spinal cord ischemia-reperfusion injury represents a devastating clinical challenge, often resulting in irreversible neurological deficits due to the abrupt lack of oxygen and subsequent restoration of blood flow. The event triggers a cascade of oxidative stress and cell death pathways, with ferroptosis emerging as a critical mediator. Unlike apoptosis or necrosis, ferroptosis is characterized by iron-dependent lipid peroxidation leading to catastrophic neuronal demise. However, the molecular regulators orchestrating this pathway, particularly in the context of SCIRI, have remained elusive—until now.

The research team from a leading neurobiology institute conducted a meticulous investigation into the role of HMOX1, an enzyme well-known for its cytoprotective function through heme degradation and antioxidant production. Their data demonstrate that HMOX1 does not act in isolation but physically interacts with BNIP3, a protein implicated in mitochondrial quality control and programmed cell death. This interaction appears to be a decisive factor in modulating the balance between protective mitophagy and destructive ferroptosis in affected neurons.

Mitophagy, the selective autophagic clearance of damaged mitochondria, is an essential cellular survival mechanism following ischemic insult. The study provides compelling evidence that the HMOX1-BNIP3 complex induces mitophagy, which in turn mitigates the accumulation of dysfunctional mitochondria that could otherwise precipitate excessive reactive oxygen species (ROS) production and trigger ferroptotic cascades. Through sophisticated in vivo and in vitro models of SCIRI, the researchers showed that enhancing this protein interaction promoted neuronal survival by scavenging mitochondria damaged during reperfusion injury.

Mechanistically, the study elucidates how HMOX1-dependent modulation of BNIP3 expression augments the mitophagic flux, effectively curbing ROS overload and lipid peroxidation processes integral to ferroptosis. Blocking either HMOX1 or BNIP3 expression resulted in reduced mitophagy, exacerbated oxidative damage, and heightened ferroptotic cell death, highlighting the therapeutic potential of this pathway. These insights deepen our understanding of the fine-tuned molecular crosstalk that dictates neuronal fate post-injury.

The team’s use of advanced molecular biology techniques, including co-immunoprecipitation, confocal microscopy, and ferroptosis-specific assays, authenticated the physical and functional partnerships between HMOX1 and BNIP3. Moreover, they deployed pharmacological agents to modulate these pathways, demonstrating that targeted enhancement of HMOX1-BNIP3 activity could serve as a viable neuroprotective intervention. This discovery aligns with the broader landscape of precision medicine, aiming to inhibit ferroptosis selectively while preserving essential cellular processes.

Intriguingly, the findings shed light on the dualistic nature of HMOX1, which has typically been associated with antioxidative defense but now emerges as a pivotal regulator of mitochondrial dynamics via BNIP3. This dual role underscores the complexity of intracellular signaling in response to ischemic stress and opens new avenues for exploring how mitochondrial health intersects with cell death regulation, particularly in neurons that are highly susceptible to oxidative insults.

The modulation of neuronal ferroptosis through mitophagy mediated by HMOX1-BNIP3 interaction offers a fresh perspective on how spinal cord repair mechanisms can be amplified. It challenges existing paradigms which mostly focus on broad antioxidative therapies, suggesting that more precise targeting of protein interactions and organelle quality control may yield superior clinical outcomes following spinal cord injury.

Importantly, these findings have broader implications beyond SCIRI. Ferroptosis is increasingly implicated in a variety of neurodegenerative diseases and acute brain injuries. Understanding how mitophagy dynamically regulates ferroptotic pathways could inspire new treatments across a spectrum of neurological conditions where mitochondrial dysfunction and oxidative stress are central hallmarks.

Furthermore, the study prompts a reevaluation of current pharmacologic strategies that have overlooked the interplay between iron metabolism, mitochondrial turnover, and regulated cell death. Targeting the HMOX1-BNIP3 axis might offer a novel mechanistic foothold to design better therapies that concurrently promote mitochondrial health and prevent ferroptosis, ultimately preserving neuronal function.

These discoveries also underscore the importance of mitophagy as a protective cellular mechanism. By removing damaged mitochondria, mitophagy reduces the intracellular iron pool that catalyzes lipid peroxidation, the defining step in ferroptosis. Therefore, enhancing mitophagy via HMOX1-BNIP3 not only stabilizes mitochondrial populations but also lowers the threshold for ferroptotic induction, positioning this pathway at the nexus of neuroprotection.

The research also emphasizes temporal dynamics, revealing that the peak interaction and resultant mitophagy activation occur during the critical window following reperfusion. Timing therapeutic interventions to coincide with this window may maximize efficacy, a finding that could guide clinical protocols for managing spinal cord trauma patients.

Translating these findings into clinical practice will require further investigation to develop modulators or gene therapies capable of enhancing the HMOX1-BNIP3 axis in humans. The safety profile must be carefully evaluated to avoid unwanted effects, as perturbations in mitophagy and ferroptosis could have diverse consequences depending on cell type and injury context.

In conclusion, this seminal study from Duan et al. offers a transformative insight into the molecular underpinnings of neuronal ferroptosis after spinal cord ischemia-reperfusion injury. By illuminating how HMOX1 collaborates with BNIP3 to activate mitophagy and curb ferroptosis, the research charts a promising course towards novel therapies that harness intrinsic cellular processes to foster neural resilience and repair. This advancement signals a new chapter in neurotrauma research, blending molecular precision with therapeutic innovation.

As the field progresses, these revelations will likely catalyze a paradigm shift in addressing the vast unmet needs of spinal cord injury patients, whose recovery has long been hindered by limited treatment options. Harnessing the mitophagy-ferroptosis axis may soon become a cornerstone of regenerative neurology, transforming dire prognoses into hopeful futures.

Subject of Research: Interaction between HMOX1 and BNIP3 proteins in regulating neuronal ferroptosis via mitophagy after spinal cord ischemia-reperfusion injury.

Article Title: HMOX1 interacts with BNIP3 to modulate neuronal ferroptosis after spinal cord ischemia-reperfusion injury via a mitophagy-dependent mechanism.

Article References:
Duan, Y., Zhang, Y., Yang, F. et al. HMOX1 interacts with BNIP3 to modulate neuronal ferroptosis after spinal cord ischemia-reperfusion injury via a mitophagy-dependent mechanism. Cell Death Discov. 11, 536 (2025). https://doi.org/10.1038/s41420-025-02831-z

Image Credits: AI Generated

DOI: 10.1038/s41420-025-02831-z